Liraglutide increases islet Ca2+ oscillation frequency and insulin secretion by activating hyperpolarization‐activated cyclic nucleotide‐gated channels
Abstract Aim To determine whether hyperpolarization‐activated cyclic nucleotide‐gated (HCN) channels impact glucagon‐like peptide‐1 (GLP‐1) receptor (GLP‐1R) modulation of islet Ca2+ handling and insulin secretion. Methods The impact of liraglutide (GLP‐1 analogue) on islet Ca2+ handling, HCN currents and insulin secretion was monitored with fluorescence microscopy, electrophysiology and enzyme immunoassays, respectively. Furthermore, liraglutide‐mediated β‐to‐δ‐cell cross‐communication was assessed following selective ablation of either mouse islet δ or β cells. Results Liraglutide increased β‐cell Ca2+ oscillation frequency in mouse and human islets under stimulatory glucose conditions. This was dependent in part on liraglutide activation of HCN channels, which also enhanced insulin secretion. Similarly, liraglutide activation of HCN channels also increased β‐cell Ca2+ oscillation frequency in islets from rodents exposed to a diabetogenic diet. Interestingly, liraglutide accelerated Ca2+ oscillations in a majority of islet δ cells, which showed synchronized Ca2+ oscillations equivalent to β cells; therefore, we assessed if either cell type was driving this liraglutide‐mediated islet Ca2+ response. Although δ‐cell loss did not impact liraglutide‐mediated increase in β‐cell Ca2+ oscillation frequency, β‐cell ablation attenuated liraglutide‐facilitated acceleration of δ‐cell Ca2+ oscillations. Conclusion The data presented here show that liraglutide‐induced stimulation of islet HCN channels augments Ca2+ oscillation frequency. As insulin secretion oscillates with β‐cell Ca2+, these findings have important implications for pulsatile insulin secretion that is probably enhanced by liraglutide activation of HCN channels and therapeutics that target GLP‐1Rs for treating diabetes. Furthermore, these studies suggest that liraglutide as well as GLP‐1‐based therapies enhance δ‐cell Ca2+ oscillation frequency and somatostatin secretion kinetics in a β‐cell‐dependent manner..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Diabetes, Obesity and Metabolism - 24(2022), 9, Seite 1741-1752 |
| Beteiligte Personen: |
Zaborska, Karolina E. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 John Wiley & Sons Ltd. |
|---|
| Umfang: |
12 |
|---|
| doi: |
10.1111/dom.14747 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY004639049 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY004639049 | ||
| 003 | DE-627 | ||
| 005 | 20230307140519.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230214s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/dom.14747 |2 doi | |
| 028 | 5 | 2 | |a DOM_DOM14747.xml |
| 035 | |a (DE-627)WLY004639049 | ||
| 035 | |a (WILEY)DOM14747 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.76 |2 bkl | ||
| 084 | |a 44.89 |2 bkl | ||
| 100 | 1 | |a Zaborska, Karolina E. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Liraglutide increases islet Ca2+ oscillation frequency and insulin secretion by activating hyperpolarization‐activated cyclic nucleotide‐gated channels |
| 264 | 1 | |c 2022 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 John Wiley & Sons Ltd. | ||
| 520 | |a Abstract Aim To determine whether hyperpolarization‐activated cyclic nucleotide‐gated (HCN) channels impact glucagon‐like peptide‐1 (GLP‐1) receptor (GLP‐1R) modulation of islet Ca2+ handling and insulin secretion. Methods The impact of liraglutide (GLP‐1 analogue) on islet Ca2+ handling, HCN currents and insulin secretion was monitored with fluorescence microscopy, electrophysiology and enzyme immunoassays, respectively. Furthermore, liraglutide‐mediated β‐to‐δ‐cell cross‐communication was assessed following selective ablation of either mouse islet δ or β cells. Results Liraglutide increased β‐cell Ca2+ oscillation frequency in mouse and human islets under stimulatory glucose conditions. This was dependent in part on liraglutide activation of HCN channels, which also enhanced insulin secretion. Similarly, liraglutide activation of HCN channels also increased β‐cell Ca2+ oscillation frequency in islets from rodents exposed to a diabetogenic diet. Interestingly, liraglutide accelerated Ca2+ oscillations in a majority of islet δ cells, which showed synchronized Ca2+ oscillations equivalent to β cells; therefore, we assessed if either cell type was driving this liraglutide‐mediated islet Ca2+ response. Although δ‐cell loss did not impact liraglutide‐mediated increase in β‐cell Ca2+ oscillation frequency, β‐cell ablation attenuated liraglutide‐facilitated acceleration of δ‐cell Ca2+ oscillations. Conclusion The data presented here show that liraglutide‐induced stimulation of islet HCN channels augments Ca2+ oscillation frequency. As insulin secretion oscillates with β‐cell Ca2+, these findings have important implications for pulsatile insulin secretion that is probably enhanced by liraglutide activation of HCN channels and therapeutics that target GLP‐1Rs for treating diabetes. Furthermore, these studies suggest that liraglutide as well as GLP‐1‐based therapies enhance δ‐cell Ca2+ oscillation frequency and somatostatin secretion kinetics in a β‐cell‐dependent manner. | ||
| 700 | 1 | |a Jordan, Kelli L. |4 aut | |
| 700 | 1 | |a Thorson, Ariel S. |4 aut | |
| 700 | 1 | |a Dadi, Prasanna K. |4 aut | |
| 700 | 1 | |a Schaub, Charles M. |4 aut | |
| 700 | 1 | |a Nakhe, Arya Y. |4 aut | |
| 700 | 1 | |a Dickerson, Matthew T. |4 aut | |
| 700 | 1 | |a Lynch, Joshua C. |4 aut | |
| 700 | 1 | |a Weiss, Adam J. |4 aut | |
| 700 | 1 | |a Dobson, Jordyn R. |4 aut | |
| 700 | 1 | |a Jacobson, David A. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes, Obesity and Metabolism |g 24(2022), 9, Seite 1741-1752 |w (DE-627)WLY004624327 |x 14631326 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2022 |g number:9 |g pages:1741-1752 |g extent:12 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.76 |q ASE |
| 936 | b | k | |a 44.89 |q ASE |
| 951 | |a AR | ||
| 952 | |d 24 |j 2022 |e 9 |h 1741-1752 |g 12 | ||